MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Neurology

Volumn 82, Issue 17, 2014, Pages 1491-1498

  Fox, Robert J ^a   Cree, Bruce A C ^b   De Séze, Jerome ^c   Gold, Ralf ^d   Hartung, Hans Peter ^e   Jeffery, Douglas ^f   Kappos, Ludwig ^g   Kaufman, Michael ^h   Montalbán, Xavier ⁱ   Weinstock Guttman, Bianca ^j   Anderson, Britt ^k   Natarajan, Amy ^l   Ticho, Barry ^l   Duda, Petra ^l  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HÔPITAL CIVIL   (France)

^d ST JOSEF HOSPITAL   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f CMC Myers Park Clinic MS Center   (United States)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h CAROLINAS MEDICAL CENTER   (United States)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j JACOBS NEUROLOGICAL INSTITUTE   (United States)

^k Infusion Communications Inc   (United States)

^l BIOGEN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; BRAIN ABSCESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPESTHESIA; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PEPTIDES; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902197646     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000355     Document Type: Article

References (24)

1. Polman CH, O'Connor PW, Havrdova E, et al A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
2. Rudick RA, Stuart WH, Calabresi P.A., et al Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
3. Bloomgren G, Richman S, Hotermans C., et al Risk of natalizumab- associated progressive multifocal leukoen-cephalopathy. N Engl J Med 2012; 366:1870-1880.
4. Fox RJ, Rudick RA Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436-437.
5. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35-47.
6. Wenning W, Haghikia A, Laubenberger J., et al Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075-1080.
7. Borriello G, Prosperini L, Marinelli F., Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011; 17:372-375.
8. Borriello G, Prosperini L, Mancinelli C., Gianni C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012; 19:783-787.
9. Havla J, Gerdes LA, Meinl I, et al De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011; 258:1665-1669.
10. Kaufman MD, Lee R, Norton HJ Course of relapsing-remitting multiple sclerosis before, during and after nata-lizumab. Mult Scler 2011; 17:490-494.
11. Kerbrat A, Le Page E, Leray E, et al Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308:98-102.
12. Killestein J, Vennegoor A, Strijbis E.M., et al Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68:392-395.
13. Magraner MJ, Coret F, Navarre A., et al Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011; 258: 1805-1811.
14. Rossi S, Motta C, Studer V., et al Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2013; 20:87-94.
15. West TW, Cree BA Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68:395-399.
16. Rinaldi F, Seppi D, Calabrese M., Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640-1643.
17. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, et al Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013; 128:e6-e10.
18. Miravalle A, Jensen R, Kinkel RP Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68:186-191.
19. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag B.M., Polman CH Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70:1150-1151. (Pubitemid 351464749)
20. O'Connor P.W., Goodman A, Kappos L., et al Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76:1858-1865.
21. Stüve O., Cravens PD, Frohman E.M., et al Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72:396-401.
22. Cree B, De Seze J, Fox R, et al RESTORE study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity. Neurology 2012; 78:P06.168.
23. Centonze D, Rossi S, Rinaldi F., Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79:2004-2005.
24. Grimaldi LM, Prosperini L, Vitello G., Borriello G, Fubelli F, Pozzilli C. MRI-based analysis of natalizumab therapeutic window in multiple sclerosis. Mult Scler 2012; 18:1337-1339.